Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Sources History of glucagon-like peptide-1 receptor agonists (ScienceDirect) Mechanisms of GLP-1 Receptor Agonist Induced Weight Loss (The American Journal of Medicine) Real-world weight loss with semaglutide 2.4 mg or tirzepatide, approval dates (Advances in Therapy, Springer) FDA Approves New Medication for Chronic Weight Management, Zepbound (U.S
Glycemic control Mean hemoglobin A1c decreased from 9.06 1.69% at baseline to 8.75 2.48% at the most recent available assessment, corresponding to a mean change of 0.31 2.57% (p = 0.630)
Cost and practicality
Tirzepatide causes more weight loss than semaglutide May 20, 2025 Summary: An 18-month study shows that tirzepatide (Zepbound) leads to more weight loss than semaglutide (Wegovy), although both are exceptionally effective at promoting clinically significant weight loss
